Home Breast Cancer Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant...

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant – Schwartz – – The Oncologist

63
0

Corresponding Author

Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA

Correspondence: Todd W. Miller, Ph.D., Geisel School of Medicine at Dartmouth, DHMC, One Medical Center Drive, Rubin 670, Lebanon, New Hampshire 03756, USA. Telephone: 6036539284; e‐mail: [email protected]; or Gary Schwartz, , Geisel School of Medicine at Dartmouth, DHMC, One Medical Center Drive, Rubin 670, Lebanon, New Hampshire 03756, USA. Telephone: ; e‐mail: [email protected]Search for more papers by this author

https://theoncologist.onlinelibrary.wiley.com/doi/abs/10.1002/onco.13733

This site uses Akismet to reduce spam. Learn how your comment data is processed.